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Abstract: The report aims to investigate the relationship between the expression of cyclin 
D1  and  Cyclooxgenase-2  (COX-2),  thus  to  explore  the  molecular  mechanisms  of  the 
antitumor efficacy of Celecoxib, a COX-2 inhibitor. Human ovarian SKOV-3 carcinoma 
cell xenograft-bearing mice were treated with Celecoxib by infusing gaster (i.g.) twice/day 
for 21 days. The mRNA levels of COX-2 and cyclin D1 were determined by RT-PCR. The 
expression of cyclin D1 at the protein level was detected by immunohistochemistry, while 
COX-2 protein expression was determined by  Western blot. A high-dose of Celecoxib 
(100 mg/kg) significantly inhibited tumor growth (P < 0.05), and the expression of cyclin 
D1  was  reduced  by  61%.  Celecoxib  decreased  the  proliferation  cell  index  by  40% 
(P < 0.001)  and  increased  apoptotic  index  by  52%  (P < 0.05)  in  high-dose  Celecoxib 
treated group. Our results suggest that the antitumor efficacy of Celecoxib against ovarian 
cancer in mice may in part be mediated through suppression of cyclin D1, which may 
contribute to its ability to suppress proliferation. 
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1. Introduction  
Ovarian cancer is an insidious disease that has few specific symptoms in the early stages and most 
women  with  this  disease  present  with  an  advanced  stage  at  the  time  of  diagnosis.  The  current 
management of advanced epithelial ovarian cancer generally includes cytoreductive surgery followed 
by  combination  chemotherapy,  but  the  long-term  survival  of  ovarian  cancer  patients  remains 
unsatisfactory [1]. Therefore, searching for new alternative agents for the prevention and treatment of 
ovarian cancer is essential. 
Cyclooxgenase-2  (COX-2)  is  inducible  by  inflammatory  stimuli,  including  cytokines,  growth 
factors, and tumor promoters, and is upregulated in a variety of malignancies and favors the growth of 
malignant cells by stimulating proliferation and angiogenesis [2,3]. Recently, large number of studies 
demonstrated that COX-2 is over-expressed in ovarian cancer [4–6]. Furthermore, Arico et al. found 
that COX-2 can induce angiogenesis via vascular endothelial growth factor (VEGF) and prostaglandin 
production  and  can  also  inhibit  apoptosis  by  inducing  the  antiapoptotic  factor  Bcl-2  as  well  as 
activating antiapoptotic signaling through Akt/PKB (one of the serine/threonine kinases) [7]. These 
results suggest that COX-2 plays an important role in the generation and progression of solid tumors, 
and inhibition of COX-2 may inhibit the growth of a variety of solid malignancies. In addition, many 
reports  have  revealed  that  COX-2  inhibitor  therapy  could  be  beneficial  in  the  prevention  and/or 
treatment of ovarian cancer [8–10]. Celecoxib, a COX-2 inhibitor, inhibits meningioma growth in vivo 
at plasma levels achievable in humans, and the tumors treated with Celecoxib had low expression of 
COX-2 and were less vascular with increased apoptosis [11]. The research indicated that Celecoxib has 
a direct effect on COX-2 protein expression in an in vivo model of spontaneous metastatic breast 
cancer  [12],  and  the  COX-2  expression  decreased  correspondingly  with  an  increasing  dose  of 
Celecoxib in human colorectal adenocarcinoma cells [13]. One of the main anticancer mechanisms of 
Celecoxib  is  to decrease production of prostaglandins in  the COX-2 expressing neovasculature of 
tumors, resulting in an inhibition of proliferation and induction of apoptosis in both the vasculature and 
the tumor [14].  
Cyclin D1, one of the cell cycle proteins, affects the proliferation of a cell. The expression of cyclin 
D1 might be responsible for progression and/or ultimately tumorigenesis of human ovarian cancer 
epithelial tissues [15]. In epithelial ovarian cancer, overexpression of cyclin D1 has been associated 
with decreased survival in patients [16]. Therefore, it has been hypothesized that a decrease of cyclin 
D1 could be potentially effective in inhibiting proliferation of tumor cells. In this study, to discuss the 
relationship between COX-2 and cyclin D1, we investigated the potential effect of Celecoxib on the 
growth of malignant ovarian tumors in a SKOV-3 cells mouse xenograft model and aimed to elucidate 
the molecular mechanism of its antitumor effect in relation to cyclin D1. 
2. Results and Discussion  
2.1. Inhibition of Ovarian Cancer Growth 
To  test  whether  Celecoxib  could  inhibit  ovarian  cancer  growth,  we  used  the  human  ovarian 
carcinoma cell line SKOV-3. SKOV-3 cells were implanted into the subcutaneous growth, so that 
changes in tumor growth could be easily monitored. The tumor growth increased throughout the period Int. J. Mol. Sci. 2010, 11                       
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examined in the vehicle-treated group. After three weeks of treatment with high dose of Celecoxib and 
5-Fu, mean tumor volumes in the group treated with Celecoxib was 2425 ±  71 mm
3, in mice with 5-Fu 
was  2230 ±  12 mm
3.  Under  similar  conditions,  the  mean  tumor  volume  in  control  mice  was 
2900 ±  55 mm
3. Tumor growth was significantly reduced during the end of treatment period with high 
doses of Celecoxib and 5-Fu treatment (P < 0.05, all). No toxicity was observed in any of the animals 
as measured by weight gain/loss as well as gross pathological examination of the gastrointestinal tract 
of the animals at necropsy. 
2.2. Celecoxib Decreases COX-2 and Cyclin D1 Expression in Tumors 
COX-2 expression was evaluated by Western blot and RT-PCR. These analyses revealed that after 
Celecoxib treatment (100 mg/kg), the expression of the COX-2 protein was substantially decreased in 
mouse ovarian carcinoma (Figure 1A). To evaluate the expression of cyclin D1 in Celecoxib-treated 
mice,  protein  and  mRNA  changes  in  drug-treated  xenograft  tumors  were  detected  by 
immunohistochemistry  and  RT-PCR  analysis.  Immunohistochemistry  analysis  revealed  that 
quantification of cyclin D1-postive cells showed 47.00% of cells in the control versus 28.33% of cells 
(P < 0.05) in the group treated with a high-dose of Celecoxib (Figure 1B). As shown in Figure 1C, 
Celecoxib (100 mg/kg) significantly decreased the mRNA expression levels of cyclin D1 compared 
with the control (P < 0.05), and it also decreased the expression of COX-2 mRNA levels. 
2.3. Effect on VEGF Production  
In this report, we measured VEGF levels in xenograft tumors by real-time PCR analysis. Four 
molecular  isoforms  of  VEGF  are  generated  by  alternative  splicing,  rendering  proteins  containing  
206-,  189-,  165-  and  121-amino  acid  residues  [17].  Although  VEGF  206  transcripts  were  not 
amplified, VEGF 189, 165 and 121 were routinely detected in this series of ovarian cancer. Real-time 
PCR analysis indicated the ΔCT (cycle threshold, = CTselected  gene – CTβ-actin) of VEGF in the four 
groups shown in Table 1. Comparing the results of the control and treatment groups, the expression 
levels of VEGF mRNA were significantly suppressed in all treatment groups (all P < 0.05, Figure 2). 
As  the  dose  of  Celecoxib  increased,  the  inhibition  of  mRNA  expression  was  more  pronounced 
(P < 0.05). The results showed a dose-dependent inhibition of the expression of VEGF mRNA after 
treated with Celecoxib. 
Table 1. The ΔCT of VEGF in four groups. Molecular isoforms of VEGF are generated by 
alternative splicing, rendering proteins containing 189-, 165- and 121-amino acid residues. 
VEGF 189, 165 and 121 were routinely detected in this series of ovarian cancer. 
  Control  Celecoxib (25 mg)  Celecoxib (100 mg)  5-FU 
VEGF 121  3.55 ±  0.17  3.72 ±  0.16  4.91 ±  0.22  5.47 ±  0.19 
VEGF 165  3.28 ±  0.21  5.00 ±  0.19  5.13 ±  0.19  6.12 ±  0.24 
VEGF 189  4.72 ±  0.17  5.58 ±  0.12  5.70 ±  0.34  6.02 ±  0.29 Int. J. Mol. Sci. 2010, 11                       
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Figure 1. Effects of Celecoxib on COX-2 and cyclin D1 activation in SKOV-3 xenograft 
tumors:  (A)  Western  blot  analysis  of  SKOV-3  tumors  treated  with  a  high-dose  of 
Celecoxib (100 mg/kg). Tumor cells lysate protein from six control mice (T1–T6) and six  
Celecoxib-treatment  mice  (T7–T12);  (B)  Representative  pictures  of  cyclin  D1 
immunohistochemical  staining  of  tumors.  Magnification  is  × 400;  (C)  mRNA  levels  of 
COX-2 and cyclin D1 detected by RT-PCR. The results show that both COX-2 and cyclin 
D1  expression  in  tumors  were  decreased  in  the  high-dose  Celecoxib  treatment  group.  
*P < 0.05 compared with control, error bars indicate SE. 
(A) 
 
(B) 
 
(C) 
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Figure 2. Effects of the drugs on the expression of VEGF. mRNA levels of VEGF were 
decreased in treatment groups. *P < 0.05 compared with control, 
#P < 0.05 compared with 
Celecoxib-25 mg group, error bars indicate SE. 
 
2.4. Celecoxib Inhibits Tumor Cell Proliferation and Induces Apoptosis 
To  further  characterize  the  antitumor  activity  of  COX-2  inhibition,  we  compared  tumor  tissue 
proliferation index and apoptosis index of Celecoxib/5-Fu-treated mice with vehicle-treated control 
mice. The quantification of the Ki-67-positive cells in the tumors showed that high-dose Celecoxib 
treatment to nude mice results in a decrease in proliferation index compared with control (Figure 3A). 
As shown in Figure 3B, statistically significant differences in tumor proliferation inhibition were noted 
between the high-dose Celecoxib treatment and control group (33.67 ±  2.11% versus 56.50 ±  2.00%, 
P < 0.05).  In  addition,  a  statistically  significant  difference  was  observed  between  the  low-  and  
high-dose  Celecoxib  treatment  groups  (48.67 ±  4.21%  versus  33.67 ±  2.11,  P < 0.05).  The  results  
of this experiment comparing the proliferation index of tumors treatment with low- and high-dose 
Celecoxib showed a trend toward a dose-dependent proliferation inhibition response.  
To evaluate the extent of apoptosis in tumor tissue in a cancer-bearing mouse model, apoptotic cells 
were stained by the TUNEL method and the number of apoptotic-positive cells was counted in a  
high-power field. We observed an increase in apoptotic-positive cells in Celecoxib/5-Fu-treated tumor 
sections  as  compared  with  control  tumor  sections  (Figure  4A).  The  index  of  apoptotic  cells  was 
significantly  higher  in  the  Celecoxib  and  5-Fu  treatment  groups  than  in  the  control  group  (all  
P < 0.05, Figure 4B). 
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Figure  3.  COX-2  inhibitor  effect  on  the  proliferation  of  tumors:  (A)  representative 
photomicrograph of Ki-67 staining of tumor tissue; (B) proliferation index. Quantitative 
data for the proliferation index is shown as percent of Ki-67-postive cells. Proliferation 
index illustrates the proliferation inhibition of Celecoxib on tumors. *P < 0.05 compared 
with  control, 
#P  <  0.05  compared  with  low-dose  Celecoxib  treated  group,  error  bars 
indicate SE. 
(A) 
 
(B) 
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Figure 4. COX-2 inhibitor effect on the apoptosis of tumors. (A) Apoptotic cells of tumor 
tissue.  Light  microscopic  image  of  TUNEL-positive  cells  visualizing  apoptosis  from 
ovarian tumor sections isolated from vehicle, 5-Fu and 25, 100 mg/kg Celecoxib-treated 
mice. Brown, apoptotic cells. All images are representative of five standardized fields from 
six separate mice. Magnification × 400. (B) Apoptotic index. Quantitative data for apoptotic 
index is shown as percent TUNEL-postive cells. Apoptotic index illustrates the apoptotic 
indution of Celecoxib on tumors. *P < 0.05 compared with control, error bars indicate SE. 
(A) 
 
(B) 
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2.5. Discussion 
The  central  finding  in  the  present  study  was  that  Celecoxib  suppressed  the  growth  of  human  
ovarian  SKOV-3  carcinoma  xenografts  in  athymic  nude  mice  without  any  noticeable  toxicity.  
High-dose Celecoxib showed greater antitumor efficacy than low-dose Celecoxib, and the antitumor 
effect of Celecoxib was associated with a decrease in proliferation index as observed by reduced cyclin 
D1 expression, a increase in apoptosis, and a strong inhibition of tumor angiogenesis as observed by 
VEGF analyses.  
There is ample evidence to suggest an important role for COX-2 in cancer. Many reports indicate 
that COX-2 is up-regulated [4–6] and its expression is an independent prognostic factor [18] in human 
ovarian carcinoma. These results suggest that COX-2 plays an important role in the generation and 
progression of ovarian cancer, and inhibition of COX-2 may restrain the growth of ovarian cancer. 
Treatment with Aspirin caused cell growth inhibition and induces apoptosis in ovarian cancer cell 
lines,  and  also  caused  a  time-dependent  regression  of  xenograft  tumors  in  mice  [8].  In  ovarian 
carcinoma  cells,  treatment  with  the  COX-2  specific  inhibitor  NS-398  reduced  Lipse  Activator  
(LPA)-induced  promatrix  metalloproteinase-2  (proMMP-2)  protein  expression  and  activation  and 
blocked MMP-dependent motility and invasive activity [19]. Other reports also revealed that selective 
COX-2 inhibition suppressed the growth of OVCAR-3 xenograft tumors of ovarian cancer [8,9]. The 
views that COX-2 is up-regulated in ovarian carcinoma and COX-2 inhibitor can restrain the growth of 
human ovarian cancer xenograft tumors are widely accepted by researchers. However, the molecular 
mechanism of their antitumor effect is still in discussion. 
Cyclin  D1,  which  correlates  with  enhanced  proliferation,  is  one  of  the  cell  cycle  proteins 
responsible for transition to the S phase (DNA synthesis) of the cell cycle, and its overexpression is 
associated  with  malignant  transformation.  Research  has  demonstrated  that  an  estimated  26%  of 
sporadic epithelial ovarian cancers overexpress cyclin D1 [20]. Another study also showed that cyclin 
D1  plays  a  dominant  role  in  regulating  cell  cycle  progression  in  ovarian  cancer  cells  and  that 
degradation of cyclin D1 is sufficient to induce G1 cell cycle arrest [21]. In this study we investigated 
the  expression  of  cyclin  D1  in  ovarian  carcinoma  xenografts  and  the  relationship  between  the 
antitumor  effect  of  Celecoxib  and  the  expression  of  cyclin  D1.  We  investigated  this  relationship 
because research had previously reported that COX-2 [4–6] and cyclin D1 [20] were both up-regulated 
in  ovarian  cancer.  In  ovarian  cancer  SKOV3  cells,  the  expression  of  COX-2  protein  was 
downregulated  by  Celecoxib  treatment  [22].  Cyclin  D1  is  rarely  mutated,  but  its  overexpression 
confers a selective growth advantage and hence acts as driver of neoplastic growth in various cancers 
[23].  Therefore,  we  suspected  that  there  was  a  connection  between  COX-2  and  cyclin  D1.  A 
corresponding decrease in cyclin D1-positive cells as well as their mRNA and protein expression by 
Celecoxib (100 mg/kg) was also observed. The results of our study manifested that there is a parallel 
decrease in the mRNA expression level of COX-2 and cyclin D1 in response to high-dose Celecoxib 
treatments, which confirmed our suppose. The discovery raised the possibility that Celecoxib inhibits 
the expression of Cyclin D1 by a COX-2 dependent mechanism and that up-regulation of cyclin D1 in 
ovarian cancer is induced by COX-2. In the case of celecoxib, the modulation of cyclin D1 levels 
appears to be a unique response because it was only observed in some cancer cell lines and it seems to 
be  COX-2  dependent  because  it  occurs  in  COX-2  overexpressing  cell  lines.  Schiffmann  et  al. Int. J. Mol. Sci. 2010, 11                       
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demonstrated that treatment of COX-2-negative HCT-116 human colon cancer cells with celecoxib 
reduced  cyclin  D1  expression,  while  in  COX-2-overexpressing  HCA-7  cells,  celecoxib  and 
methylcelecoxib  (lack  COX-2-inhibitory  activity)  caused  a  weaker  degradation  of  cyclin  D1 
expression [24]. In addition, Celecoxib inhibited growth of SW480 human colon cancer cells through 
inhibiting subcellular cGMP-phosphodiesterase (PDE) enzymatic activity associated with a decrease  
in cellular levels of cyclin D1, while a high concentration of the COX-2 specific inhibitor rofecoxib 
did  not  inhibit  growth  of  SW480  cells  [25].  This  research  in  colon  cancer  cells  manifested  that  
COX-independent mechanisms may play a distinct role in the anti-proliferative effect of Celecoxib.  
Unchecked cell proliferation is necessary for solid tumor growth and progression. Cancer cells often 
have a selective growth advantage due to deregulation of cell cycle proteins, causing aberrant growth 
signaling that drives tumor development [26,27]. In this study, we have shown that the tumor growth 
inhibition by Celecoxib was accompanied by a decrease in proliferation index, and that high-dose 
Celecoxib exhibited greater efficacy in proliferation inhibition of human ovarian carcinoma SKOV-3 
cells.  The  results  suggested  that  Celecoxib  may  inhibit  cell  cycle  progression  through  the  G1-S 
transition in SKOV-3 cells in vivo by decreasing the expression of cyclin D1 as one of its potential 
antiproliferative  mechanisms.  Celecoxib-caused  inhibition  of  tumor  cell  proliferation  could  be 
associated  with  G1  phase  arrest  during  cell  cycle  progression.  The  hypothesis  to  explain  the 
relationship between the decrease of cyclin D1 and the G1 cell cycle arrest is that the loss of cyclin D1 
results in recruitment of p21 to cyclin E2-cdk2 complexes, inhibiting cdk2 activity, which prevents 
pRb hyperphosphorylation, and that the E2F promoters remain repressed by the bound pRb complex, 
resulting  in  G1  arrest  [21].  The  antiproliferative  effects  of  Celecoxib  could  be  attributed  to  the 
inhibition  of cell survival  signaling in  ovarian  cancer. Similar results  could  not  be observed after 
treatment with Celecoxib in rat prostate cancer cells [28].  
In addition to inhibiting proliferation, either low-dose or high-dose Celecoxib induced apoptosis in 
tumor cells compared with vehicle-treated group. Apoptosis is a multistep process and an increasing 
number of genes have been identified to be involved in the control or execution of apoptosis [29]. 
Recently, Uddin et al. [10] demonstrated that COX-2 inhibition induced apoptosis via inactivation of 
pAKT, resulting in disruption of mitochondrial membrane potential, which in turn leads to release of 
cytochrome C into the cytosol. Release of cytochrome C was associated with activation of caspase 
activity, eventually resulting in apoptosis. Celecoxib effectively inhibited cell growth  and induced 
apoptosis in human ovarian cancer cells dependent upon the functional status of p53 [30]. Thus, a clear 
picture of the exact pathways by which COX-2 inhibitors induce apoptosis has yet to emerge. 
Ovarian cancer growth is angiogenesis-dependent [31,32], and secretion of proangiogenic growth 
factors such as VEGF is of prognostic value [33,34]. Strong VEGF expression was suggested to play 
an important role in the tumor progression of ovarian carcinoma [35]. VEGF is a contributing factor in 
angiogenesis, a line of evidence reveals that the elevated COX-2 expression correlates with increased 
VEGF level in human ovarian cancer [36,37]. COX-2 can induce angiogenesis via VEGF [7]. In this 
study,  Celecoxib  strongly  decreased  the  level  of  VEGF  mRNA  expression  in  ovarian  SKOV-3 
carcinoma  xenografts  both  in  the  high-  and  low-dose  drug  treatment  group  and  showed  a  
dose-dependent inhibition of the expression of VEGF mRNA. The decrease in tumor-associated VEGF 
by Celecoxib could be one of the important mechanisms in controlling angiogenesis and causing an 
inhibition of overall tumor growth. Together, our findings suggested that the antiangiogenic potential Int. J. Mol. Sci. 2010, 11                       
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of Celecoxib could be explored for lowering the risk of and preventing the growth and progression of 
ovarian cancer.  
3. Experimental Section 
3.1. Human Ovarian Tumors in Nude Mice 
SKOV-3 cells were used for tumor growth studies in vivo. The SKOV-3 cells were purchased from 
China  Type  Culture  Collection  and  grown  in  the  recommended  media  under  standard  condition. 
SKOV-3 cells were inoculated subcutaneously into the right axillary region (5 ×  10
6 cells) of female 
BALB/cA nude mice (nu/nu, 6–7 weeks old). When the average tumor reached around 141–147 mm
3, 
the mice were randomly separated into four groups (6 mice in each group). Mice were treated every 
other  day  by  oral  gavage  with  Celecoxib  (25 mg/kg  and  100 mg/kg  i.g.  twice/day)  or  vehicle 
(i.g. twice/day), i.p. injection with 5-Fu (20 mg/kg i.p. once/day), respectively from d1 to d21. All 
methods  used in  this  study were approved by  the Animal Subjects  Programs  of Nanjing Medical 
University  and  conform  to  Health  guidelines  and  public  law  of  the  People’s  Republic  of  China. 
Celecoxib was purchased from Pfizer Pharmaceutical Co. (Dalian, China), and 5-Fu was purchased 
from Xudong Haipu Pharmaceutical Co. (Shanghai, China). Celecoxib was suspended in vehicle (5% 
methylcellulose and 0.025% Tween 20) at appropriate concentrations and orally administered to the 
mice. The tumor dimensions were measured twice a week using a linear caliper, and tumor volume 
was calculated using the equation V (mm
3) = a ×  b
2/2, where a is the largest diameter and b is the 
smallest diameter. Tumor growth was evaluated by the inhibition rate as assessed by the formula:  
IR = C − T/C ×  100%, where IR is the mean inhibition rate, T is the mean tumor volume in the 
treatment group and C is the mean tumor volume in the control group. The animals were weighed 
weekly  throughout  the  experiment.  On  day  28,  all  of  the  mice  were  sacrificed,  and  tumor  tissue 
samples  were  collected  and  then  fixed  in  10%  phosphate-buffered  formalin  solution  for 
immunohistology or snap-frozen in liquid nitrogen before storage at −80 ° C until analysis.  
3.2. Real-Time PCR 
Total  RNA  was  extracted  using  TRIzol  reagents  (Life  Technologies),  according  to  the 
manufacturer’s instructions. Isolated RNA was electrophoresed through 1.0% agarose-formaldehyde 
gels to verify the quality of the RNA. The first strand cDNA was generated by reverse transcription. 
After  a  sufficient  amount  of  cDNA  was  obtained,  we  performed  PCR  amplification  using  a  
real-time PCR cycler (7500 ABI, USA). COX-2, cyclin D1 and VEGF 189/165/121 were routinely 
detected  in  this  series  of  ovarian  cancer.  The  sequences  of  PCR  primers  were:  
COX-2,  5'-AGACAGCGACGCCAAGCCAC-3'  and  5'-GGCGAGCGCGCAAAACCAAA-3';  
VEGF  (121),  5'-ACTCGGATGCCGACACGGGA-3'  and  5'-CCTGGCCTTGCTTGCTCCCC-3'; 
VEGF  (165),  5'-CCAGGATCCTCTGCCCGCCT-3'  and  5'-GCGGCTTCCGGCACCTACAG-3'; 
VEGF  (189),  5'-GGCAAAAGTTGCGAGCCGCC-3'  and  5'-TGGATGGACCGGGAGCAGGG-3'; 
Cyclin  D1,  5'-AAGCCGCTTTTCCACGGCGA-3'  and  5'-AGGCTCCCCGGCTTCCACTT-3';  
β-actin, 5'-GGGTGACGAGGCCCAGAGCA-3' and 5'-GGGGCCACACGCAGCTCATT-3'.  Int. J. Mol. Sci. 2010, 11                       
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The amplification system included 50 μL of SYBRGreen Mix (32.5 μL), ddH2O (14.5 μL), cDNA 
(2 μL), forward primer (0.5 μL) and reverse primer (0.5 μL). The reaction conditions were as follows: 
Stage 1, 50 °C  for 2.00 min (1 cycle); Stage 2, 95 ° C for 5.00 min (1 cycle); Stage 3, 95 ° C for 
0.25 min followed by 60 ° C for 0.75 min (40 cycles); Stage 4, 95 ° C for 0.25 min firstly, then 60 ° C 
for 1.00 min, and lastly, 95 ° C for 0.25 min followed by 60 ° C for 0.25 min (1 cycle).  
The results of real-time PCR were analyzed by the DCT method: ΔCT = CTselected gene − CTβ-actin,  
RQ (Relative Quantitation) = 2
−ΔCT ×  100%. The results of real-time PCR were presented as the ratio 
between the selected genes and β-actin transcripts. 
3.3. Western Blot 
Lysates (40 μg of protein/lane) were analyzed by SDS-PAGE on 12% Tris-glycine gels. Protein was 
electrotransferred to nitrocellulose membranes and blocked with a solution of PBS containing 5% milk 
and 0.1% Tween 20. Bands were detected using chemiluminescent detection reagents (GE healthcare, 
code:  RPN2106).  Blots  were  probed  with  a  goat  polyclonal  antibody  against  COX-2  (Beijing 
biosynthesis  biotechnology  Co.,  China.  code:  BS-0732R)  followed  by  a  peroxidase-conjugated 
antigoat (abcam), respectively. After incubation, antibodies were washed in PBS and 0.1% Tween 20. 
Bands were detected using chemiluminescent detection reagents (GE healthcare, code: RPN2106). 
3.4. TUNEL 
Apoptosis  was  measured  in  tissue  sections  by  the  terminal  deoxyribonucleotidyl  
transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay as described by Gavrieli et al. [38] 
with some modifications. In this study, apoptosis was detected by the TUNEL kit (Chemicon Co. 
China).  The  tissue  samples  were  fixed  in  4%  paraformaldehyde  (PFA)  for  24  h,  dehydrated,  and 
embedded  in  paraffin  in  the  conventional  manner.  The  paraffin-embedded  tissues  were  cut  into  
4 μm-thick  sections.  After  deparaffinization  in  a  graded  alcohol  series,  the  tissue  sections  were  
covered with 20 μg proteinase K/mL PBS (–) for 15 min at room temperature, followed by blocking  
of  endogenous  peroxidase  activity.  The  samples  were  then  incubated  with  TdT  enzyme  and  
biotin-16-dUTP in TdT buffer containing 0.01% bovine serum albumin for 1.5 h at 37 ° C in a humidity 
chamber. Biotin-16-dUTP nucleotides that had been incorporated into DNA fragments were detected 
using the ABC method with DAB as the chromogen. In each tissue specimen, five high-power fields 
(× 400 magnification) were randomly selected, the apoptotic index (AI) was calculated in these fields as 
the percentage of positive cells, given by the following equation [39]:  
AI = (number of positive cells/total number of cells) ×  100% 
3.5. Immunohistochemistry 
Proliferation index was evaluated by staining for Ki-67. At the same time, cyclin D1 protein was 
also  detected  by  immunohistochemistry.  Tumors  were  fixed  in  10%  neutral  buffered  formalin  for  
24–48 h prior to being embedded in paraffin. After deparaffinization, the tissue sections were heated at 
121 ° C for 15 min in  10 mM  TrisHCl  with  1  mM  EDTA  (pH 9.0). Endogenous peroxidase  was 
blocked with 3% hydrogen peroxide in methanol for 10 min at room temperature. The samples were Int. J. Mol. Sci. 2010, 11                       
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incubated  with  Ki-67  antibody  (clone  MIB-5  (M7248))  or  cyclin  D1  antibody  (Santa  Cruz 
Biotechnology, USA) for 90 min at room temperature. Then, the sections were incubated in EnVision 
reagent for 40 min and DAB/H2O2 for 8–12 min at room temperature. Proliferation was assessed by 
counting the number of Ki-67 positively staining nuclei and total number of cancer cells at  × 400 
magnification in five representative regions of the tumor. Results are expressed as the proportion of 
positively staining cells over the total number of cells. For evaluation of the cyclin D1 staining, the 
tissues  were  scored  for  the  protein  by  assessing  the  site  of  positive  staining  in  the  nucleus  or 
cytoplasm. The status of nuclear expression of cyclin D1 was assessed by determining the percentage 
of positive cells stained in five fields of each tissue section at × 400 magnification.  
3.6. Statistical Analyses  
Statistical  analysis  was  performed  with  SPSS  software  (SPSS  Standard  version  17.0,  SPSS). 
Statistical significance between control and treated groups was determined by Student’s t-test. We 
used a Dunnett's test for evaluation of the inhibitory activity on tumor growth. All the experimental 
data were expressed as  means values ±  SE. Results were considered statistically significant  when  
P values < 0.05. 
4. Conclusions 
The present findings provide evidence for antiproliferative, apoptosis-inducing and antiangiogenic 
effects of Celecoxib, which were associated with the inhibition of human ovarian SKOV-3 cancer 
xenograft growth without any toxicity in mice. Downregulation of cyclin D1 expression via a COX-2 
dependent mechanism by Celecoxib could be a potential in vivo mechanism to inhibit ovarian cancer 
growth.  Targeting  cyclin  D1  may  be  one  of  the  molecular  mechanisms  restraining  the  growth  of 
ovarian cancer by COX-2 inhibition. Celecoxib might inhibit the expression of cyclin D1 by a COX-2 
dependent mechanism. 
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